SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

March 9, 2018: By Joan McKenna

SightLifeSurgicalSightLife Surgical has acquired the KAMRA corneal inlay from AcuFocus, the two companies announced March 8.

Terms were not disclosed.

AcuFocus, in Irvine, California, said the move allows it to focus on commercializing its IC-8 small aperture intraocular lens in the US market.

AcuFocus KAMRA

AcuFocus KAMRA

SightLife Surgical, a Seattle-based subsidiary of the nonprofit SightLife, said the KAMRA fits into its mission to eliminate corneal blindness by 2040. SightLife Surgical provides corneal tissue and medical devices to surgeons for corneal transplants.

The KAMRA gained US approval in April 2015 for the surgical correction of presbyopia. The opaque mini-ring is designed to use the pinhole effect to extend depth of focus in presbyopic patients.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales